Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WILLOW LTE study of Enpatoran in participants with cutaneous and/or systemic lupus erythematosus
CTR20222533Phase 2Active
- Sponsor
- Merck KGaA
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enpatoran in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), sponsored by Merck KGaA. Started Mar 2023; status: active.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on CTR20222533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222533.